MDAI: Difference between revisions
From DMT-Nexus Wiki
Jump to navigationJump to search
Added safety profile |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
* Nausea, headache, tiredness, depression, rise in blood pressure | * Nausea, headache, tiredness, depression, rise in blood pressure | ||
| | | | ||
* Mental addiction | * Mental addiction. WARNING: Some studies have shown that much of what is sold online as "MDAI" actually contains mephedrone or other similar drugs. | ||
| | | | ||
* Cardiovascular toxicity has not been tested. As of 2013, | * Cardiovascular toxicity has not been tested. As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN! | ||
}} | }} | ||
== Brief overview - What is MDAI? == | == Brief overview - What is MDAI? == | ||
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects | 5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects. | ||
Latest revision as of 21:24, 19 December 2013
| Safety profile |  |
|---|---|
Category:
|
|
Main effects:
|
|
Side effects:
|
|
Health risks:
|
|
Important safety remarks:
|
|
Brief overview - What is MDAI?
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.
